MedPath

Promoting Improved Functioning Among People Experiencing Stressful Situations

Not Applicable
Recruiting
Conditions
Acute Stress Reaction
Interventions
Behavioral: Physical Presence with Reassurance
Behavioral: iCOVER
Registration Number
NCT06482567
Lead Sponsor
University of North Carolina, Chapel Hill
Brief Summary

The iCOVER intervention was developed to rapidly restore functioning in individuals experiencing an Acute Stress Reaction (ASR). iCOVER is undergoing widespread adoption but has not been tested for efficacy. iCOVER was designed to be administered by peers, paraprofessionals, or medical personnel in 60-120 seconds, including in military operational environments. The term iCOVER is an acronym that summarizes the six specific steps of the intervention: (1) identify that an individual is experiencing an ASR; (2) Connect with the individual through word, eye contact, and physical touch to draw them back to the present moment; (3) Offer commitment so that the individual feels less psychologically isolated and withdrawn (e.g., "I'm right here with you"); (4) Verify facts - ask simple fact-based questions to engage the individual in deliberate cognitive activity; (5) Establish order of events - briefly review what has happened, what is happening, and what will happen to orient the individual; and (6) Request action to re-engage the individual in purposeful behavior.

Participants will be randomly assigned to one of three groups: iCOVER, usual care, or physical presence with reassurance. Investigators have elected to use two different control conditions, in order to examine the reliability of the iCOVER intervention in comparison with two typical responses to individuals experiencing an ASR (i.e., physical presence with reassurance, no specific treatment).

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
450
Inclusion Criteria
  • ≥ 18 years and ≤ 50 years of age (if age not known, appears to be)
  • In the emergency department as a patient or loved one of a patient
  • If a patient, anticipated to be discharged to home from the emergency department after evaluation
  • Exhibiting visible signs of distress Richmond Agitation and Sedation Scale ((RASS) (+1 to +3)) or dissociation (awake and alert but reduced responsiveness)
  • Likely able to speak English
Read More
Exclusion Criteria
  • Known pregnancy
  • Prisoner or in custody
  • Known history of psychosis or bipolar disorder
  • Known or suspected drug intoxication
  • Known history of substantial cognitive impairment
  • Known or suspected altered mental status due to traumatic brain injury
  • Known active psychosis, suicidal ideation, or homicidal ideation
  • Unable to use both hands (e.g. due to sprain)
  • Any other history or condition that would, in the site investigator's judgement, indicate that the individual would very likely be non-compliant with the study or unsuitable for the study (e.g. might interfere with the study, confound interpretation, or endanger participant)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Physical Presence with ReassurancePhysical Presence with ReassuranceA research assistant (RA) will stay with the participant for the length of the iCOVER intervention (in order to ensure matching of the amount of time spent with individuals who receive the iCOVER intervention, which takes 60-120 seconds). During this time, the RA will provide supportive but passive statements. The RA will leave the participant after the length of the iCOVER intervention has elapsed. A separate blinded RA will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
iCOVERiCOVERIndividuals randomized to the iCOVER arm will be approached by a trained RA who will obtain assent and perform the iCOVER intervention. After completing the iCOVER protocol, the unblinded RA will leave, and a blinded outcome assessor will return 5 minutes post-intervention to conduct the immediate post-intervention assessment.
Primary Outcome Measures
NameTimeMethod
Neurocognitive function at the immediate post-intervention assessmentImmediately post-intervention (5 mins)

To assess acute neurocognitive function, a suite of four brief neurocognitive tasks will be employed, and the primary outcome will consist of overall performance across all four tasks as assessed jointly using a multivariate linear mixed model. These four tasks each assess an aspect of neurocognitive function essential to warfighting during times of intense stress: generalized cognitive function using the Test My Brain Digit Symbol Matching Test (measuring balanced integration scores (BIS) which combine accuracy with mean reaction time for correct responses to 'test' trials), procedural reaction using the Test My Brain Choice Reaction Time Test (measuring the mean and median reaction times for correct responses to 'test' trials, as well as through BIS values, which incorporate normalized meanRTc.), visual search and visual change detection using the Test My Brain Multiple Object Tracking Test (measuring percent correct for the proportion of total targets correctly identified).

Secondary Outcome Measures
NameTimeMethod
Test My Brain Digit Symbol Matching5 mins, 1 hour, 2 days, 7 days post-intervention

General cognitive function will be assessed using the Test My Brain Digit Symbol Matching Test. Participants will be asked to match as many symbols and numbers as possible in 90 seconds, using a symbol-number key shown on screen. General cognitive function is assessed via balanced integration scores (BIS), which combine accuracy with mean reaction time for correct responses to 'test' trials

Test My Brain Choice Reaction Time Test5 mins, 1 hour, 2 days, 7 days post-intervention

Procedural reaction time will be assessed using the Test My Brain Choice Reaction Time Test. In this 3-minute task, participants see a set of three arrows, where one arrow is a different color from the rest. The participant presses left or right to indicate the direction of the odd colored arrow. Reaction time is assessed via measuring the mean and median reaction times for correct responses to 'test' trials, as well as through BIS values, which incorporate normalized meanRTc.

Test My Brain Multiple Object Tracking Test5 mins, 1 hour, 2 days, 7 days post-intervention

Visuospatial processing and attention will be assessed will be performed using the Test My Brain Multiple Object Tracking Test. In this two-minute test of visuospatial processing and attention, participants have to track a set of target circles around the screen (amidst a field of distractors) that move at increasing speed with each trial. Once the circles stop moving, participants select which were targets must identify targets instead of distractors. Visuospatial processing and attention is assessed via measuring percent correct for the proportion of total targets correctly identified.

Test My Brain Gradual Onset Continuous Performance Test5 mins, 1 hour, 2 days, 7 days post-intervention

Psychomotor vigilance will be assessed via the Test My Brain Gradual Onset Continuous Performance Test. In this 1-minute task, participants monitor a stream of city and mountain images that rapidly fade from one to the next with no interstimulus interval. Participants are asked to press/touch for each city image and to withhold for each mountain image. Vigilance is assessed via measuring d-prime for identification of each city image, a signal detection-based measure that takes into account both hits and false alarms to provide an unbiased estimate of performance where higher values reflect better performance. Response inhibition is defined as the suppression of actions that are inappropriate in a given context. Response inhibition is assessed using results from the above, by measuring the number of commission errors (failure to withhold responses) where most positive scores reflect more impulsive responding.

Total time spent attempting the four Test My Brain neurocognitive tests5 min post-intervention

Length of time individual spends attempting the four neurocognitive tests will be recorded until either discontinuation or completion of tests.

Subjective Distress assessed via the Subjective Units of Distress (SUDS) scale5 mins, 1 hour, 2 days, 7 days post-intervention

Individuals will be asked verbally to rate their subjective distress at each assessment timepoint on a scale from 0 (totally relaxed) to 100 (highest distress/fear/anxiety you have ever experienced).

Acute Stress Disorder symptoms severity assessed via the Acute Stress Disorder Scale2 days, 7 days post-intervention

Individuals are asked to complete the 19-item Acute Stress Disorder Scale (ASDS) self-report inventory where each item is rated on a 5-point scale (0= Not at all; 1= A little bit; 2= Moderately; 3= Quite a bit; 4= Extremely) that indexes acute stress disorder (ASD).

Sleep Quality assessed using the Insomnia Severity Index2 days, 7 days post-intervention

Individuals are asked to complete the 7-item self-report Insomnia Severity Index (ISI) questionnaire where each item is rated on a 0-4 scale (0= none; 1= mild; 2= moderate; 3= severe; 4= very severe) (that assesses the severity, nature, and impact of insomnia over the past two weeks.

Functional Impairment using the PROMIS Global Health Scale v1.22 days, 7 days post-intervention

Individuals are asked to complete the 10-item PROMIS Global Health questionnaire where the first 9-items are rated on a 1-5 scale (1= poor; 2= fair; 3= good; 4= very good; 5= excellent) and the one remaining item is rated on a 0-10 scale (0= no pain; 10= worst pain imaginable) that measures a patient's physical, mental, and social health.

Acute Stress Reaction symptoms using the Stress Monitoring and Response Tool (SMART)1 hour, 2 days, 7 days post-intervention

Individuals are asked to complete the 34-item SMART tool where the first 11-items are rated on a 0-10 scale (0= none; 10= severe) and the remaining 23-items are rated on a 0-10 scale (0=none; 10= a great deal) that briefly evaluates core Acute Stress Reaction (ASR) symptom domains including pain, somatic, depressive, concentration, and fatigue symptoms. Question responses will be used to create latent variables for each ASR domain at each timepoint, and ASR symptom severity between groups across timepoints will be assessed.

Trial Locations

Locations (5)

McLean Hospital, Harvard Medical School

🇺🇸

Belmont, Massachusetts, United States

University of Massachusetts Chan Medical School

🇺🇸

Worcester, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Washington University, St. Louis

🇺🇸

Saint Louis, Missouri, United States

Cooper University Health Care

🇺🇸

Camden, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath